Vivek Podder, MBBS

⭐️Wow 👉🏼published in @Nature 👉🏼“Thymic health and immunotherapy outcomes in patients with cancer.” ⭐️Across melanoma, breast, & renal cancers, the signal is clear: thymic health is a pan‑cancer, #tumoragnostic determinant of immunotherapy efficacy. ⭐️I think there are huge implications for patient stratification, treatment timing, & immune‑rejuvenating strategies in #PrecisionMedicine here @OncoAlert nature.com/articles/s4158…

#Obesity is associated with higher risk for 12 #cancer types and accounts for approximately 10% of annual new cancer cases in the US. 📄 This Review summarizes the primary biological pathways connecting obesity and cancer development. ja.ma/3OPhtgT

@amazon One of the worst customer service experiences I have encountered. Multiple cancellations, account flags, repeated refund promises not honored, and inconsistent interactions from associates. Far from the customer-centric positioning. @ajassy @AmitAgarwal @JeffBezos

Now online: Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities doi.org/10.1158/1078-0…

Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. ja.ma/4ih8jV1

Join us for November Journal Club!  Wednesday, November 19th, 2025 11:00-11:45 CST (18:00-18:45 CET). November Lead Article for Discussion: Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy igcs.org/ijgc-journal-c…

✨ Don’t miss our next #IJGCclub! 🗓️ Nov 19 | 11:00 CDT (18:00 CEST) 📖 Checkpoint inhibitor rechallenge in advanced endometrial cancer with Brian M. Slomovitz, MD @GynCancerMD and Vivek Podder @VPodder (@SinaiHealth) 🔗 Don’t miss this engaging discussion: bit.ly/4jfSMEP @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @IJGCfellows @OncoAlert @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

Emerging Therapeutics in Low-Grade Serous Ovarian Carcinoma - @VPodder oncodaily.com/voices/vivek-p… #Cancer #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag

#LeadArticle Checkpoint inhibitor rechallenge in advanced #endometrialcancer: revisiting the immune landscape beyond first-line therapy ✅ bit.ly/48W0QIh @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul @GynCancerMD @VPodder

We just published in @TheLancetOncol a very important paper regarding the new FDA guidance on overall survival assessment in cancer drug trials. Right in time for #ESMO25. Please do read. I promise you that you’ll learn something that’s applicable broadly. And follow along this thread for a broader discussion of the points we make in this paper. thelancet.com/journals/lanon…

Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of #endometrialcancer 🧬 bit.ly/48K1s3N @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul

Onclive State of the Science Coming to Miami 10/30 Hosted by @OncLive @MountSinaiMiami Join us for a great way to learn and to network with friends and colleagues. So honored have this distinguished group of Key Opinion Leaders as speakers @DrKatyMoore @IJGConline @GOG

NEW: FDA releases draft guidance on overall survival assessment in oncology trials, with an emphasis on analyzing overall survival as a pre-specified safety endpoint. fda.gov/regulatory-inf…

We need better treatments for our patients with advanced/metastatic cervix cancer!!! Open and accruing @MountSinaiMiami clinicaltrials.gov/study/NCT06459…

@AskeBay @eBay I made a high-value purchase in June (~$639). The item turned out to be counterfeit. Seller now “no longer a registered user.” eBay suspended my account, blocked returns & denied Money Back Guarantee after I disputed w/ Discover. I need an urgent resolution @FTC

The man in seat 11A survived, but why don’t our patients? dlvr.it/TLRd9l #Physician #PrimaryCare via @kevinmd

The man in seat 11A survived, but why don’t our patients? kevinmd.com/2025/06/the-ma… via @kevinmd

Honored to be a co-investigator on this practice changing trial. @GOG @MountSinaiMiami

telemundo51.com/noticias/local… Honored to be investigator using Tisotumab Vedotin @pfizer @Genmab that received @FDAOncology @US_FDA approval for women with cervical cancer. Grateful to @Telemundo for helping to raise cervical cancer awareness @igcs @IJGConline @GOG @MountSinaiMiami